Dermatology

EMA CHMP recommends CMA for Boehringer’s spesolimab to treat GPP flares

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicine Agency (EMA) has recommended granting conditional marketing authorization (CMA) for…

Torrent Pharma to acquire Curatio for $245.16m

Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn). The deal comprises cash and…

How environmental factors could influence disease and drugs

The study of lifetime exposures, also known as the “exposome”, is providing a new perspective on how environmental and social…

EC grants approval for BMS’ Opdualag to treat melanoma

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) fixed-dose combination, Opdualag (nivolumab and relatlimab), as first-line therapy…

US FDA grants approval for BMS’ Sotyktu to treat plaque psoriasis

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib) to treat adult patients…

Quoin and Endo sign supply deal for QRX003 in Canada

Quoin Pharmaceuticals and Endo International subsidiary Endo Ventures have signed a licence and distribution agreement and a supply agreement to develop,…

Health Canada to review Arcutis’ roflumilast cream NDS for plaque psoriasis

Health Canada has accepted to review Arcutis Biotherapeutics’ New Drug Submission (NDS) for roflumilast cream 0.3% (ARQ-151) to treat plaque psoriasis in…

Alopecia: Can new treatments pass the innovation and safety bar?

Last Friday, the US FDA decided to keep the popular anti-baldness drug finasteride on the market, but is now requiring…

Vitiligo: all eyes on further Phase III data for Incyte’s ruxolitinib at AAD

This year’s American Academy of Dermatology (AAD) Annual Meeting is already in full swing in Boston, and all eyes will…

Quoin expands distribution deal with ER-Kim for Netherton Syndrome therapy

Quoin Pharmaceuticals and ER-Kim have expanded their exclusive distribution agreement for the former’s investigational therapy, QRX003, to treat Netherton Syndrome.…

Pfizer signs agreement to acquire Arena Pharmaceuticals for $6.7bn

Pfizer has signed a definitive agreement for the acquisition of all the outstanding shares of clinical-stage firm Arena Pharmaceuticals in…

Impending regulatory approvals in atopic dermatitis (AD)

The atopic dermatitis (AD) space is changing rapidly, but the availability of new therapies across the US and Europe has…

Africa has seen the largest growth in dermatology related trials over the past decade

Africa has seen a 425% increase in the number of dermatology trials taking place over the past decade, the largest…

EMA accepts to review Boehringer’s MAA for spesolimab

The European Medicines Agency (EMA) has accepted to review Boehringer Ingelheim’s marketing authorization application (MAA) for spesolimab to treat flares…

Gut-skin axis may hold the answer to hidradenitis suppurativa

At the 30th European Academy of Dermatology and Venereology (EADV) Congress held from 29 September to 2 October, results were…